ABSTRACT
There was performed a comparative analysis of quantitative load and physical status of human papillomavirus (HPV) type 16 in groups of patients with cervical intraepithelial neoplasia (CIN)--25 people and cervical cancer (CC)--85 people. According to the analysis there were selected criteria appropriate to a combination of adverse factors that characterized HPV- infection and at the same time estimated both quantitative load and physical status of the virus: high viral load (> 6,5 lg copies of HPV DNA per 100000 cells) in episomal form or low load (< 6,5 lg copies of HPV DNA per 100000 cells) in integrated form of the virus. According to calculations a relative chance of appearing of CC in CIN patients with unfavorable combination of factors was 7,5 times higher than in other patients.
Subject(s)
Cell Transformation, Neoplastic , Cervix Uteri/pathology , Cervix Uteri/virology , Human papillomavirus 16/isolation & purification , Papillomavirus Infections/complications , Uterine Cervical Dysplasia/virology , Uterine Cervical Neoplasms/virology , Adult , Aged , DNA, Viral/isolation & purification , Female , Human papillomavirus 16/genetics , Humans , Middle Aged , Neoplasm Staging , Papillomavirus Infections/virology , Prognosis , Risk , Uterine Cervical Neoplasms/pathology , Viral LoadABSTRACT
For the 83 patients with HPV 16-cancer of the cervix (cervical cancer) I-III stages it was performed a comparative analysis of primary tumor response to therapy, the clinical outcome of the disease for 3-5 years after radical treatment and an evaluation of the possible contribution in these rates of the physical status of the virus. It was shown that total tumors regression in the early stages of the observation predominate in patients with "high-integrated" virus DNA (the degree of integration > 50%) of compared with a group of patients with episomal and "low-integrated" form of the virus, but in a distant periods (3-5 years) in the first group predominate an adverse outcome of disease. This pattern is true for tumors of stage I-III, and for less common--I-II stages. It is assumed that the integration of HPV16 DNA into the cellular genome may serve as an independent predictor of clinical outcome of cervical cancer.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemoradiotherapy , Genome, Human , Human papillomavirus 16/pathogenicity , Papillomavirus Infections/complications , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/therapy , Adult , Aged , Comparative Effectiveness Research , DNA, Viral/analysis , Disease-Free Survival , Female , Fluorouracil/administration & dosage , Human papillomavirus 16/genetics , Humans , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Papillomavirus Infections/virology , Platinum Compounds/administration & dosage , Polymerase Chain Reaction , Predictive Value of Tests , Prognosis , Treatment Outcome , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/virologyABSTRACT
The changes in blood coagulative properties, which occur in the treatment with medical leeches, were studied in 57 patients with coronary heart, rheumatic and chronic pulmonary diseases. Hirudin therapy was established to affect blood coagulation. The leech salina penetrated into the skin wound to block hemostasis. Having entered the circulating blood, some part of the saliva normalized its impaired coagulative properties. The correction of the above abnormalities and related bleeding indicate it beneficial to use hirudin therapy in secondary coagulopathies and circulatory decompensation.
